Optimization of Polymyxin B Regimens for the Treatment of Carbapenem-resistant Organism Nosocomial Pneumonia: a Real-world Prospective Study

Overview

Journal Crit Care

Specialty Critical Care

Date 2023 Apr 27

PMID 37106370

Authors

Tiantian Tang

Ying Li

Ping Xu

Yanjun Zhong

Min Yang

Wanjun Ma

Daxiong Xiang

Bikui Zhang

Yangang Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Polymyxin B is the first-line therapy for Carbapenem-resistant organism (CRO) nosocomial pneumonia. However, clinical data for its pharmacokinetic/pharmacodynamic (PK/PD) relationship are limited. This study aimed to investigate the relationship between polymyxin B exposure and efficacy for the treatment of CRO pneumonia in critically ill patients, and to optimize the individual dosing regimens.

Methods: Patients treated with polymyxin B for CRO pneumonia were enrolled. Blood samples were assayed using a validated high-performance liquid chromatography-tandem mass spectrometry method. Population PK analysis and Monte Carlo simulation were performed using Phoenix NLME software. Logistic regression analyses and receiver operating characteristic (ROC) curve were employed to identify the significant predictors and PK/PD indices of polymyxin B efficacy.

Results: A total of 105 patients were included, and the population PK model was developed based on 295 plasma concentrations. AUC/MIC (AOR = 0.97, 95% CI 0.95-0.99, p = 0.009), daily dose (AOR = 0.98, 95% CI 0.97-0.99, p = 0.028), and combination of inhaled polymyxin B (AOR = 0.32, 95% CI 0.11-0.94, p = 0.039) were independent risk factors for polymyxin B efficacy. ROC curve showed that AUC/MIC is the most predictive PK/PD index of polymyxin B for the treatment of nosocomial pneumonia caused by CRO, and the optimal cutoff point value was 66.9 in patients receiving combination therapy with another antimicrobial. Model-based simulation suggests that the maintaining daily dose of 75 and 100 mg Q12 h could achieve ≥ 90% PTA of this clinical target at MIC values ≤ 0.5 and 1 mg/L, respectively. For patients unable to achieve the target concentration by intravenous administration, adjunctive inhalation of polymyxin B would be beneficial.

Conclusions: For CRO pneumonia, daily dose of 75 and 100 mg Q12 h was recommended for clinical efficacy. Inhalation of polymyxin B is beneficial for patients who cannot achieve the target concentration by intravenous administration.

Citing Articles

The challenges of difficult-to-treat infections.

Richards G, Perovic O, Brink A Clin Microbiol Rev. 2024; 37(4):e0009324.

PMID: 39555919 PMC: 11629631. DOI: 10.1128/cmr.00093-24.

Risk Factors Associated with Antibiotic Exposure Variability in Critically Ill Patients: A Systematic Review.

Gras-Martin L, Plaza-Diaz A, Zarate-Tamames B, Vera-Artazcoz P, Torres O, Bastida C Antibiotics (Basel). 2024; 13(9).

PMID: 39334976 PMC: 11428266. DOI: 10.3390/antibiotics13090801.

Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistant an and analysis.

Sturaro M, Damaceno N, Faccin I, Silva O, Aquino T, Freire N Antimicrob Agents Chemother. 2024; 68(10):e0093024.

PMID: 39254296 PMC: 11459926. DOI: 10.1128/aac.00930-24.

Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China.

Li L, Huang X, Liu J, Li C, Lin Z, Ren R Infect Drug Resist. 2024; 17:3057-3071.

PMID: 39050834 PMC: 11268568. DOI: 10.2147/IDR.S468890.

Polymyxins: recent advances and challenges.

Yang S, Wang H, Zhao D, Zhang S, Hu C Front Pharmacol. 2024; 15:1424765.

PMID: 38974043 PMC: 11224486. DOI: 10.3389/fphar.2024.1424765.

References

Onufrak N, Rao G, Forrest A, Pogue J, Scheetz M, Nation R . Critical Need for Clarity in Polymyxin B Dosing. Antimicrob Agents Chemother. 2017; 61(5). PMC: 5404569. DOI: 10.1128/AAC.00208-17. View

Rigatto M, Behle T, Falci D, Freitas T, Lopes N, Nunes M . Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015; 70(5):1552-7. DOI: 10.1093/jac/dku561. View

Xie J, Roberts J, Lipman J, Cai Y, Wang H, Zhao N . Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. Int J Antimicrob Agents. 2020; 55(6):105943. DOI: 10.1016/j.ijantimicag.2020.105943. View

Elias L, Konzen D, Krebs J, Zavascki A . The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010; 65(10):2231-7. DOI: 10.1093/jac/dkq285. View

Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic J, Lye D, Lee L . Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2017; 104(3):534-538. DOI: 10.1002/cpt.981. View

Cheah S, Wang J, Nguyen V, Turnidge J, Li J, Nation R . New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015; 70(12):3291-7. DOI: 10.1093/jac/dkv267. View

Gupta R, Malik A, Rizvi M, Ahmed M, Singh A . Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients. J Glob Antimicrob Resist. 2017; 9:47-50. DOI: 10.1016/j.jgar.2016.12.016. View

Zhou Y, Xu P, Li H, Wang F, Yan H, Liang W . Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia. Br J Clin Pharmacol. 2020; 87(7):2838-2846. DOI: 10.1111/bcp.14692. View

Laessig K . End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective. Clin Infect Dis. 2010; 51 Suppl 1:S117-9. DOI: 10.1086/653059. View

10.

Lin Y, Zhou Q, Onufrak N, Wirth V, Chen K, Wang J . Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model. Antimicrob Agents Chemother. 2017; 61(8). PMC: 5527630. DOI: 10.1128/AAC.00211-17. View

11.

Miglis C, Rhodes N, Avedissian S, Kubin C, Yin M, Nelson B . Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. Antimicrob Agents Chemother. 2018; 62(3). PMC: 5826159. DOI: 10.1128/AAC.01475-17. View

12.

Hanafin P, Nation R, Scheetz M, Zavascki A, Sandri A, Kwa A . Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT Pharmacometrics Syst Pharmacol. 2021; 10(12):1525-1537. PMC: 8674003. DOI: 10.1002/psp4.12720. View

13.

Kalil A, Metersky M, Klompas M, Muscedere J, Sweeney D, Palmer L . Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5):e61-e111. PMC: 4981759. DOI: 10.1093/cid/ciw353. View

14.

Tran T, Velkov T, Nation R, Forrest A, Tsuji B, Bergen P . Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?. Int J Antimicrob Agents. 2016; 48(6):592-597. PMC: 5154767. DOI: 10.1016/j.ijantimicag.2016.09.010. View

15.

Tangden T, Ramos Martin V, Felton T, Nielsen E, Marchand S, Bruggemann R . The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017; 43(7):1021-1032. DOI: 10.1007/s00134-017-4780-6. View

16.

Bergen P, Bulitta J, Forrest A, Tsuji B, Li J, Nation R . Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010; 54(9):3783-9. PMC: 2934992. DOI: 10.1128/AAC.00903-09. View

17.

Li J, Nation R, Turnidge J, Milne R, Coulthard K, Rayner C . Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6(9):589-601. DOI: 10.1016/S1473-3099(06)70580-1. View

18.

Justo J, Bosso J . Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy. 2014; 35(1):28-33. DOI: 10.1002/phar.1493. View

19.

Huang Y, Jiao Y, Zhang J, Xu J, Cheng Q, Li Y . Microbial Etiology and Prognostic Factors of Ventilator-associated Pneumonia: A Multicenter Retrospective Study in Shanghai. Clin Infect Dis. 2018; 67(suppl_2):S146-S152. DOI: 10.1093/cid/ciy686. View

20.

Sobieszczyk M, Furuya E, Hay C, Pancholi P, Della-Latta P, Hammer S . Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004; 54(2):566-9. DOI: 10.1093/jac/dkh369. View